These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11866670)

  • 1. Endothelin receptor antagonists in cardiology clinical trials.
    Neunteufl T; Berger R; Pacher R
    Expert Opin Investig Drugs; 2002 Mar; 11(3):431-43. PubMed ID: 11866670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential for endothelin receptor antagonists in cardiovascular disorders.
    Spieker LE; Noll G; Lüscher TF
    Am J Cardiovasc Drugs; 2001; 1(4):293-303. PubMed ID: 14728028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible therapeutic role of endothelin antagonists in cardiovascular disease.
    Ram CV
    Am J Ther; 2003; 10(6):396-400. PubMed ID: 14624276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelin receptor antagonists.
    Motte S; McEntee K; Naeije R
    Pharmacol Ther; 2006 Jun; 110(3):386-414. PubMed ID: 16219361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The endothelin system as target for therapeutic interventions in cardiovascular and renal disease.
    Eroglu E; Kocyigit I; Lindholm B
    Clin Chim Acta; 2020 Jul; 506():92-106. PubMed ID: 32151622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis.
    Aubert JD; Juillerat-Jeanneret L
    J Med Chem; 2016 Sep; 59(18):8168-88. PubMed ID: 27266371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin.
    Kawanabe Y; Nauli SM
    Cell Mol Life Sci; 2011 Jan; 68(2):195-203. PubMed ID: 20848158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of endothelin system in cardiovascular disease and the potential therapeutic perspectives of its inhibition.
    Kaoukis A; Deftereos S; Raisakis K; Giannopoulos G; Bouras G; Panagopoulou V; Papoutsidakis N; Cleman MW; Stefanadis C
    Curr Top Med Chem; 2013; 13(2):95-114. PubMed ID: 23470073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The endothelin-aldosterone axis and cardiovascular diseases.
    Rossi GP; Cavallin M; Nussdorfer GG; Pessina AC
    J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S49-52. PubMed ID: 11811378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin receptor antagonists: clinical realities and future directions.
    Kirchengast M; Luz M
    J Cardiovasc Pharmacol; 2005 Feb; 45(2):182-91. PubMed ID: 15654268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelin receptor antagonists and cardiovascular diseases of aging.
    Love MP; McMurray JJ
    Drugs Aging; 2001; 18(6):425-40. PubMed ID: 11419917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs.
    Lüscher TF; Barton M
    Circulation; 2000 Nov; 102(19):2434-40. PubMed ID: 11067800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The therapeutic potential of endothelin receptor antagonists in cardiovascular disease.
    Barton M; Kiowski W
    Curr Hypertens Rep; 2001 Aug; 3(4):322-30. PubMed ID: 11470015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelin receptor antagonists. Promising new agents in the management of cardiovascular disorders.
    Goddard J; Webb DJ
    Drugs R D; 1999 Jul; 2(1):1-12. PubMed ID: 10560541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats.
    Sakai S; Miyauchi T; Sakurai T; Yamaguchi I; Kobayashi M; Goto K; Sugishita Y
    J Am Coll Cardiol; 1996 Nov; 28(6):1580-8. PubMed ID: 8917275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?
    Spieker LE; Noll G; Ruschitzka FT; Lüscher TF
    J Am Coll Cardiol; 2001 May; 37(6):1493-505. PubMed ID: 11345356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin in cardiovascular control: the role of endothelin antagonists.
    Wenzel RR; Czyborra P; Lüscher T; Philipp T
    Curr Hypertens Rep; 1999; 1(1):79-87. PubMed ID: 10981046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical potential of endothelin receptor antagonists in cardiovascular medicine.
    Ferro CJ; Webb DJ
    Drugs; 1996 Jan; 51(1):12-27. PubMed ID: 8741230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension.
    Tilton RG; Brock TA; Dixon RA
    Expert Opin Investig Drugs; 2001 Jul; 10(7):1291-308. PubMed ID: 11772252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New expansion of endothelin research: perspectives for clinical application of endothelin-receptor antagonists].
    Goto K; Miyauchi T
    Nihon Yakurigaku Zasshi; 2003 Feb; 121(2):91-101. PubMed ID: 12616854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.